Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Sep 1;40(9):e348-e351.
doi: 10.1097/INF.0000000000003173.

QuantiFERON-TB Gold Plus Assay Specificity in Children and Adolescents With Suspected Tuberculosis-A Multicenter Cross-sectional Study in Spain

Aleix Soler-Garcia  1 , Anna Gamell  1 , Begoña Santiago  2   3 , Manuel Monsonís  4 , Elvira Cobo-Vázquez  3 , Matilde Bustillo-Alonso  5 , Alfredo Tagarro  3   5   6 , Beatriz Pérez-Gorricho  7 , María Espiau  8 , Ana Isabel Piqueras  9 , José Javier Korta-Murua  10   11 , Paula Rodríguez-Molino  12 , Zulema Lobato  13 , Tomàs Pérez-Porcuna  14 , Marc Tebruegge  15   16   17 , Antoni Noguera-Julian  1   2   18   19 ; for the QFT-Plus Study Group of the Spanish Pediatric TB Research Network (pTBred)
Affiliations
Multicenter Study

QuantiFERON-TB Gold Plus Assay Specificity in Children and Adolescents With Suspected Tuberculosis-A Multicenter Cross-sectional Study in Spain

Aleix Soler-Garcia et al. Pediatr Infect Dis J. .

Abstract

In this cross-sectional study of 284 children and adolescents with clinically or radiologically suspected tuberculosis in a low-endemic country, the QuantiFERON-TB Gold Plus assay specificity, sensitivity, positive predictive value and negative predictive value were 91.5%, 87.3%, 86.4%, and 91.2%, respectively. The specificity was higher than that observed in tuberculin skin tests performed simultaneously, but similar to previous-generation interferon-gamma release assays.

PubMed Disclaimer

Conflict of interest statement

M.T. has received QuantiFERON assays at reduced pricing or free of charge for TB diagnostics projects from the manufacturer (Cellestis/Qiagen) in the past and has received support for conference attendance from Cepheid. The manufacturers had no influence on the study design, data collection, analysis or interpretation, writing of the manuscript, or decision to submit the data for publication. The remaining authors have no other conflicts of interest to disclose.

References

    1. WHO. Global tuberculosis report 2018. WHO 2019. Available at: https://www.who.int/tb/publications/global_report/en/ . Accessed January 10, 2021.
    1. Tebruegge M, Ritz N, Curtis N, et al. Diagnostic Tests for childhood tuberculosis: past imperfect, present tense and future perfect? Pediatr Infect Dis J. 2015;34:1014–1019.
    1. Tebruegge M, Ritz N, Koetz K, et al. Availability and use of molecular microbiological and immunological tests for the diagnosis of tuberculosis in Europe. PLoS One. 2014;9:e99129.
    1. Barcellini L, Borroni E, Brown J, et al. First evaluation of quantiFERON-TB gold plus performance in contact screening. Eur Respir J. 2016;48:1411–1419.
    1. Soler-Garcia A, Gamell A, Santiago B, et al.; QFT-Plus Study Group of the Spanish Pediatric TB Research Network (pTBred). Diagnostic accuracy of QuantiFERON-TB gold plus assays in children and adolescents with tuberculosis disease. J Pediatr. 2020;223:212–215.e1.

Publication types